Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Current Liabilities (2016 - 2025)

Vistagen Therapeutics' Total Current Liabilities history spans 12 years, with the latest figure at $13.5 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 40.62% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $13.5 million, up 40.62%, while the annual FY2025 figure was $12.6 million, 146.18% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $13.5 million at Vistagen Therapeutics, down from $13.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $13.6 million in Q3 2025 and bottomed at $2.9 million in Q3 2023.
  • The 4-year median for Total Current Liabilities is $6.4 million (2021), against an average of $7.7 million.
  • The largest annual shift saw Total Current Liabilities tumbled 84.88% in 2021 before it surged 158.57% in 2024.
  • A 4-year view of Total Current Liabilities shows it stood at $6.4 million in 2021, then tumbled by 35.14% to $4.2 million in 2023, then soared by 131.02% to $9.6 million in 2024, then surged by 40.62% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Total Current Liabilities are $13.5 million (Q4 2025), $13.6 million (Q3 2025), and $11.2 million (Q2 2025).